Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease
Blood‐based phosphorylated tau (Ptau) 181 and 217 biomarkers are sensitive and specific
for Alzheimer's disease. In this racial/ethnically diverse cohort study, participants were …
for Alzheimer's disease. In this racial/ethnically diverse cohort study, participants were …
Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines
KR Thomas, KJ Bangen, EC Edmonds… - Alzheimer's & …, 2021 - Wiley Online Library
Introduction Objectively‐defined subtle cognitive decline (Obj‐SCD) and plasma
phosphorylated‐tau181 (p‐tau181) are promising early Alzheimer's disease (AD) markers …
phosphorylated‐tau181 (p‐tau181) are promising early Alzheimer's disease (AD) markers …
Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease
Background To investigate the association of plasma pTau181, assessed with a new
immunoassay, with neurodegeneration of white matter and gray matter cross-sectionally and …
immunoassay, with neurodegeneration of white matter and gray matter cross-sectionally and …
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
J Simrén, A Leuzy, TK Karikari, A Hye… - Alzheimer's & …, 2021 - Wiley Online Library
Introduction This study investigated the diagnostic and disease‐monitoring potential of
plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) …
plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) …
Association of plasma P-tau181 with memory decline in non-demented adults
Alzheimer's disease is the leading cause of dementia worldwide and is characterized by a
long preclinical phase in which amyloid-β and tau accumulate in the absence of cognitive …
long preclinical phase in which amyloid-β and tau accumulate in the absence of cognitive …
Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease
Background Blood phosphorylated tau (p-tau) forms are promising Alzheimer's disease (AD)
biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) …
biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) …
Plasma p‐tau181 shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau
Introduction We examined the ability of plasma hyperphosphorylated tau (p‐tau) 181 to
detect cognitive impairment due to Alzheimer's disease (AD) independently and in …
detect cognitive impairment due to Alzheimer's disease (AD) independently and in …
Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
S De Meyer, J Vanbrabant… - Annals of clinical …, 2022 - Wiley Online Library
Abstract Objective Plasma phosphorylated‐tau‐181 (p‐tau181) reliably detects clinical
Alzheimer's disease (AD) as well as asymptomatic amyloid‐β (Aβ) pathology, but is …
Alzheimer's disease (AD) as well as asymptomatic amyloid‐β (Aβ) pathology, but is …
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD),
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …
Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects
JB Pereira, S Janelidze, E Stomrud, S Palmqvist… - Brain, 2021 - academic.oup.com
It is currently unclear whether plasma biomarkers can be used as independent prognostic
tools to predict changes associated with early Alzheimer's disease. In this study, we sought …
tools to predict changes associated with early Alzheimer's disease. In this study, we sought …